E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Pulmonary arterial hypertension |
|
E.1.1.1 | Medical condition in easily understood language |
Pulmonary arterial hypertension |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10064911 |
E.1.2 | Term | Pulmonary arterial hypertension |
E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
- To investigate the hemodynamic effects induced by step-wise increased doses of the IV administered natriuretic peptide ularitide in patients suffering from pulmonary arterial hypertension (PAH) - To investigate safety and tolerability of ularitide in patients suffering from PAH |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male and female patients 18 to 75 years of age 2. Known diagnosis of PAH (idiopathic, hereditary, drug-associated, due to connective tissue disease, simple congenital heart defects closed >1 year) with a) PVR >3 WU (determined at last right heart catheterization) b) Mean pulmonary arterial pressure (mPAP) ≥25 mmHg (determined at last right heart catheterization) c) Pulmonary arterial wedge pressure (PAWP) ≤15 mmHg (determined at last right heart catheterization) 3. Stable PAH background therapy for ≥3 months including endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE5) inhibitors, soluble guanylate cyclase (sGC) stimulators, prostacyclin analogues, prostacyclin-receptor agonists or any combination thereof 4. Scheduled for a control visit including right heart catherization 5. No morning intake of PAH background medication at the day of ularitide treatment 6. Negative pregnancy test (β-human chorionic gonadotropin) at screening in women of childbearing age 7. Ability to understand the purpose and risks of the study and to provide signed and dated written informed consent
|
|
E.4 | Principal exclusion criteria |
1. Known diagnosis of a) medium- or high-grade left-sided valvular disease b) hypertrophic obstructive cardiomyopathy c) chronic heart failure d) diastolic heart failure with preserved ejection fraction (HFpEF) e) state post pulmonary embolism f) clinically relevant parenchymal lung diseases as evidenced by - Ratio of forced expiratory volume in one second to forced vital capacity (FEV1/FVC ratio) of <55% of predicted - Forced vital capacity (FVC) <60% of predicted, and - Diffusion capacity of the lung for carbon dioxide (DLCO) <50% of predicted. All respiratory values must not be older than twelve months at the time of screening and documented in the medical history of the patient. If documented values were older than 12 months from screening, patient must undergo spirometry during screening for determining these values. 2. Contraindications for right heart catheterization such as uncontrolled coagulation disorders, uncontrolled disorders of cardiac excitation generation and conduction, permanent pacemaker, implanted defibrillator 3. Documented left ventricular ejection fraction <40% 4. Documented partial pressure of pulmonary arterial oxygen <50 mmHg (despite oxygen supplementation) and/or partial pressure of carbon dioxide >50 mmHg. 5. Uncontrolled severe systemic hypertension at screening, i.e. arterial hypertension >200 mmHg (systolic) or >120 mmHg (diastolic) 6. Estimated glomerular filtration rate (eGFR) <30 mL/kg/min at screening 7. Severe hepatic impairment or porphyria characterized by elevations of one or both serum transaminases (alanine-aminotransferase, aspartate-aminotransferase) >3 x upper limit of normal (ULN) or bilirubin >3 x ULN at screening 8. Use of sGC stimulators within three days prior to start of ularitide treatment 9. Use of nitric oxide donors or sacubitril-valsartan within three days prior to start of ularitide treatment 10. Known hypersensitivity to the active substance or to any of the excipients of the study drug or other natriuretic peptides 11. Known Hepatitis B or C or human immunodeficiency virus infection 12. Participation in an interventional clinical trial within one month prior to screening or 5 half-lives of the corresponding investigational medicinal product, whichever is longer 13. Active substance abuse 14. Legal incapacity or limited legal capacity 15. Breastfeeding or pregnancy 16. Employees of the sponsor or patients who are employees or relatives of the investigators 17. Patients committed to an institution by virtue of an order issued either by the judicial or the administrative authorities
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Efficacy: Maximum absolute change of the PVR from baseline at the individual maximum tolerated ularitide dose.
Safety: - Tolerability of ularitide (defined as number of patients with absence of stopping criteria) - Number of patients with premature treatment discontinuation due to safety reasons - Number of patients with a drop in SBP to values <90 mmHg (determined non-invasively)
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Primary efficacy and safety endpoints will be assessed after all patients have completed their treatment.
|
|
E.5.2 | Secondary end point(s) |
- Maximum relative change of the PVR from baseline at the individual maximum tolerated ularitide dose - Maximum absolute and relative change of PVR from baseline at each ularitide dose - Maximum absolute and relative change of SBP from baseline at each ularitide dose - Maximum absolute and relative change of diastolic blood pressure (DBP) from baseline at each ularitide dose - Maximum absolute and relative change of HR from baseline at each ularitide dose - Maximum absolute and relative change of peripheral oxygen saturation from baseline at each ularitide dose
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Secondary endpoints will be assessed after all patients have completed their treatment. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 24 |
E.8.9.1 | In the Member State concerned days | |